Search Results - "Schwid, S R"

Dose comparison trial of sustained-release fampridine in multiple sclerosis by GOODMAN, A. D, BROWN, T. R, COHEN, J. A, KRUPP, L. B, SCHAPIRO, R, SCHWID, S. R, COHEN, R, MARINUCCI, L. N, BLIGHT, A. R

“…To examine the efficacy and safety of three different doses of sustained-release fampridine in people with multiple sclerosis (MS). This multicenter,…”
Get full text

Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis by KRUPP, L. B, CHRISTODOULOU, C, SCHWID, S. R, WEINSTOCK-GUTTMAN, B, WESTERVELT, H. J, WISHART, H, MELVILLE, P, SCHERL, W. F, PAI, L.-Y, MUENZ, L. R, HE, D, BENEDICT, R. H. B, GOODMAN, A, RIZVI, S

“…The goal of this study was to determine if memory would be improved by donepezil as compared to placebo in a multicenter, double-blind, randomized clinical…”
Get full text

Cost-effectiveness of disease-modifying therapy for multiple sclerosis: A population-based study by NOYES, K, BAJORSKA, A, CHAPPEL, A, SCHWID, S. R, MEHTA, L. R, WEINSTOCK-GUTTMAN, B, HOLLOWAY, R. G, DICK, A. W

“…To evaluate the cost-effectiveness of disease-modifying therapies (DMTs) in the United States compared to basic supportive therapy without DMT for patients…”
Get full text

Quantitative risk-benefit analysis of natalizumab by THOMPSON, J. P, NOYES, K, DORSEY, E. R, SCHWID, S. R, HOLLOWAY, R. G

“…To model the long-term risks and benefits of natalizumab in individuals with relapsing multiple sclerosis (MS). We created a Markov model to evaluate treatment…”
Get full text

Assessing disability progression with the Multiple Sclerosis Functional Composite by Rudick, RA, Polman, CH, Cohen, JA, Walton, MK, Miller, AE, Confavreux, C, Lublin, FD, Hutchinson, M, O’Connor, PW, Schwid, SR, Balcer, LJ, Lynn, F, Panzara, MA, Sandrock, AW

“…Background The initial Multiple Sclerosis Functional Composite (MSFC) proposal was a three-part composite of quantitative measures of ambulation, upper…”
Get full text

Quantitative functional measures in MS: What is a reliable change? by SCHWID, S. R, GOODMAN, A. D, MCDERMOTT, M. P, BEVER, C. F, COOK, S. D

“…As a first step toward understanding which changes should be considered as meaningful, the authors assessed the reliability of quantitative functional tests on…”
Get full text

Safety of rasagiline in elderly patients with Parkinson disease by GOETZ, C. G, SCHWID, S. R, EBERLY, S. W, OAKES, D, SHOULSON, I

“…The authors examined age effects on adverse events from two randomized, controlled trials of rasagiline, comparing younger (younger than 70 years) and older…”
Get full text

Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis by DORSEY, E. R, THOMPSON, J. P, NOYES, K, DICK, A. W, HOLLOWAY, R. G, SCHWID, S. R

“…Using published data, we quantified the risk and benefits of natalizumab in relapsing multiple sclerosis using quality-adjusted life years (QALYs) as a metric…”
Get full text

Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis by SCHWID, S. R, PETRIE, M. D, MCDERMOTT, M. P, TIERNEY, D. S, MASON, D. H, GOODMAN, A. D

“…To evaluate the efficacy of 4-aminopyridine sustained release (4AP SR) (fampridine, EL-970) using quantitative measures of motor function in multiple sclerosis…”
Get full text

Proof of concept studies for tissue-protective agents in multiple sclerosis by Mehta, LR, Schwid, SR, Arnold, DL, Cutter, GR, Aradhye, S, Balcer, LJ, Calabresi, PA, Cohen, JA, Cole, PE, Glanzman, R, Goelz, S, Inglese, M, Kapoor, R, Kappos, L, Kreitman, R, Lublin, FD, Mann, A, Marrie, RA, O'Looney, P, Polman, CH, Ravina, BM, Reingold, SC, Richert, JR, Sandrock, AW, Waubant, E

“…Background There is considerable interest in tissue-protective treatments for multiple sclerosis (MS). Methods and Objectives We convened a group of MS…”
Get full text

The measurement of ambulatory impairment in multiple sclerosis by SCHWID, S. R, GOODMAN, A. D, MATTSON, D. H, MIHAI, C, DONOHOE, K. M, PETRIE, M. D, SCHEID, E. A, DUDMAN, J. T, MCDERMOTT, M. P

“…The objective of this study was to examine the relationships between continuous measures of ambulatory impairment in MS patients and their ordinal…”
Get full text

Are quantitative functional measures more sensitive to worsening MS than traditional measures? by SCHWID, S. R, GOODMAN, A. D, APATOFF, B. R, COYLE, P. K, JACOBS, L. D, KRUPP, L. B, MILLER, A. E, WENDE, K. E, BROWNSCHEIDLE, C. M

“…The authors used data collected prospectively during a multicenter trial in 133 patients with secondary progressive MS to assess the relative sensitivity of…”
Get full text

Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment by Polman, C H, Reingold, S C, Barkhof, F, Calabresi, P A, Clanet, M, Cohen, J A, Cutter, G R, Freedman, M S, Kappos, L, Lublin, F D, McFarland, H F, Metz, L M, Miller, A E, Montalban, X, O'Connor, P W, Panitch, H, Richert, J R, Petkau, J, Schwid, S R, Sormani, M P, Thompson, A J, Weinshenker, B G, Wolinsky, J S

“…The increasing number of established effective therapies for relapsing multiple sclerosis (MS) and emerging consensus for early treatment raise practical…”
Get full text

Quantitative assessment of motor fatigue and strength in MS by SCHWID, S. R, THORNTON, C. A, PANDYA, S, MANZUR, K. L, SANJAK, M, PETRIE, M. D, MCDERMOTT, M. P, GOODMAN, A. D

“…To determine the test-retest reliability of strength and fatigue measurements in patients with MS and in healthy control subjects, and to examine associations…”
Get full text

Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b by Schwid, S R, Goodman, A D, Mattson, D H

“…To report symptomatic autoimmune hyperthyroidism developing in patients with multiple sclerosis (MS) treated with interferon beta-1b (IFN-beta-1b). A…”
Get more information

Targeting immunotherapy in multiple sclerosis: a near hit and a clear miss by Schwid, S R, Noseworthy, J H

Get full text

Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis by Schwid, S R, Goodman, A D, Puzas, J E, McDermott, M P, Mattson, D H

“…Bone mineral density is reduced in patients with multiple sclerosis (MS), but the reduction has not been shown to correlate with steroid use retrospectively…”
Get more information

Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders by Cohen, Jeffrey A, Carter, Jonathan L, Kinkel, R.Philip, Schwid, Steven R

“…There is increasing impetus to begin disease-modifying therapy for relapsing multiple (R-MS) early, before the development of irreversible tissue damage and…”
Get full text

Pain associated with multiple sclerosis: Systematic review and proposed classification by O’Connor, Alec B., Schwid, Steven R., Herrmann, David N., Markman, John D., Dworkin, Robert H.

“…Pain is common in patients with multiple sclerosis (MS), but estimates of its prevalence have varied widely. The literature describing pain in MS patients…”
Get full text

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial by Goodman, Andrew D, Prof, Brown, Theodore R, MD, Krupp, Lauren B, MD, Schapiro, Randall T, MD, Schwid, Steven R, MD, Cohen, Ron, MD, Marinucci, Lawrence N, MS, Blight, Andrew R, PhD

“…Summary Background Clinical studies suggested that fampridine (4-aminopyridine) improves motor function in people with multiple sclerosis. This phase III study…”
Get full text